Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851064 | 0.93 | KDM4E (0.48) | KDM4ERAB9ANPSR1TSHRGABRA1 | |
| SCHEMBL13851063 | 0.93 | KDM4E (0.46) | KDM4ERAB9ANPSR1TSHRGABRA1 | |
| SCHEMBL14065327 | 0.88 | KDM4E (0.47) | KDM4ERAB9ANPSR1GABRA1GABRB1 | |
| SCHEMBL4716961 | 0.87 | PDE3B (0.46) | KDM4ERAB9ANPSR1TSHRPDE3B | |
| SCHEMBL13851060 | 0.85 | RAB9A (0.54) | KDM4ERAB9ANPSR1TSHRGABRA1 | |
| SCHEMBL5540834 | 0.85 | ALDH1A1 (0.46) | KDM4ERAB9ANPSR1TSHRGABRA1 | |
| SCHEMBL16999960 | 0.85 | RAB9A (0.42) | KDM4ERAB9ANPSR1GABRA1GABRB1 | |
| SCHEMBL6559833 | 0.84 | TSHR (0.46) | KDM4ETSHRGABRA1GABRA3ALDH1A1 | |
| SCHEMBL29897883 | 0.84 | TSHR (0.46) | KDM4ETSHRGABRA1GABRA3ALDH1A1 | |
| SCHEMBL5004727 | 0.82 | KDM4E (0.44) | KDM4ERAB9ANPSR1TSHRPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | VIIV HEALTHCARE CO (US) | 2015-08-13 | — | — | US | disclosed |
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | SHIONOGI & CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-8691991-B2 | 2-oxonaphthyridine-3-carboxamides HIV integrase inhibitors | SHIONOGI & CO., LTD. (JP) | 2014-04-08 | — | — | US | disclosed |
| US-20080234231-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-20080214527-A1 | Hiv Integrase Inhibitors | SHIONOGI & CO. LTD (JP) | 2008-09-04 | — | — | US | disclosed |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-09-04 | — | — | US | disclosed |
| US-20080194523-A1 | Hiv Integrase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| US-20070124152-A1 | Hiv Integrase Inhibitors | GLAXOSMITHKLINE LLC | 2007-05-31 | — | — | US | disclosed |
| EP-0274379-B1 | PROCESS FOR PREPARING PYRIDINE-2,3-DICARBOXYLIC ACID COMPOUNDS | SUGAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
| US-4973695-A | FROM UNSATURATED ALDEHYDE OR KETONE WITH OXODIESTER | SUGAI CHEMICAL IND. CO., LTD. (JP) | 1990-11-27 | — | — | US | disclosed |
| EP-0274379-A2 | Process for preparing pyridine-2,3-dicarboxylic acid compounds | SUGAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256713-A1 | 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS | BCDIN3D, DUT, SAMHD1 | KDM4E 1268/4885RAB9A 2184/4885NPSR1 4539/4885 |
| US-20080214527-A1 | Hiv Integrase Inhibitors | API5, ING2, SAMHD1 | KDM4E 1139/4885RAB9A 2691/4885NPSR1 4756/4885 |
| US-20150225399-A1 | HIV INTEGRASE INHIBITORS | ING2, API5, SAMHD1 | KDM4E 1255/4885RAB9A 2632/4885NPSR1 4734/4885 |
| US-20080214503-A1 | Hiv Integrase Inhibitors | SAMHD1, ACIN1, API5 | KDM4E 2653/4885RAB9A 2308/4885NPSR1 4818/4885 |
| US-20080194523-A1 | Hiv Integrase Inhibitors | ING2, API5, SAMHD1 | KDM4E 1183/4885RAB9A 2730/4885NPSR1 4749/4885 |
| US-20080234231-A1 | Hiv Integrase Inhibitors | ING2, API5, SAMHD1 | KDM4E 1183/4885RAB9A 2730/4885NPSR1 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.